Skip to main content

Advertisement

Table 2 Performance of the S5 methylation classifier, cytology, and HPV16/18 genotyping for detecting CIN2+ and CIN3+

From: Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping

  Sensitivity (95% CI) Specificity (95% CI) Unadjusted PPV (95% CI) Adjusted PPV* (95% CI) Unadjusted NPV (95% CI) OR (95% CI)
S5 cutoff 3.7
 CIN2+ 62.0 (50.4–72.7) 73.0 (66.9–78.5) 43.4 (34.0–53.0) 20.3 (16.7–23.9) 85.2 (79.6–89.8) 4.20 (2.59–7.54)
 CIN3+ 70.3 (56.7–81.8) 76.6 (70.7–81.9) 45.0 (35.0–55.3) 18.0 (14.3–21.7) 90.5 (85.0–94.2) 7.75 (4.21–14.3)
S5 cutoff 0.8
 CIN2+ 86.1 (76.5–92.8) 40.1 (33.8–46.6) 32.4 (26.1–39.2) 13.8 (11.5–16.0) 89.6 (82.2–94.7) 4.14 (2.10–8.14)
 CIN3+ 92.5 (91.8–97.9) 38.8 (32.9–45) 23.3 (17.8–29.6) 9.9 (8.0–11.9) 96.2 (90.6–99.0) 7.76 (3.83–21.2)
HPV16/18 and cytology for CIN2+
 HPV16/18+ 63.3 (51.7–73.9) 29.1 (23.4–35.3) 22.9 (17.5–29.1) 9.0 (7.2–10.9) 70.4 (60.3–79.2) 0.71 (0.42–1.21)
 ASCUS+ 57.0 (45.3–68.1) 62.4 (55.9–68.6) 33.6 (25.7–42.2) 14.4 (11.5–17.3) 81.3 (74.9–86.7) 2.20 (1.3–3.7)
 LSIL+ 51.9 (40.4–63.3) 68.8 (62.5–74.6) 35.7 (26.9–45.1) 15.6 (12.3–18.8) 81.1 (75.0–86.3) 2.38 (1.42–3.99)
 HSIL+ 27.8 (18.3–39.1) 95.8 (92.8–98.0) 68.8 (50.0–83.9) 42.3 (34.0–50.6) 79.9 (74.8–84.4) 8.70 (3.9–19.2)
  1. ASCUS+ atypical squamous cells of undetermined significance or worse, HSIL+ high-grade squamous intraepithelial lesion or worse, LSIL+ low-grade squamous intraepithelial lesion or worse, NEG histologically negative, CIN cervical intraepithelial neoplasia (of grades 1, 2, and 3).
  2. *Adjusted PPV = (Sn × Pr)/((Sn × Pr) + (1 − Sp ) × (1 − Pr)), where Sn is sensitivity, Sp is specificity, and Pr is the CIN2+ or CIN3+ screening prevalence in the FRIDA population-based study (10% and 6.8% respectively)